Several MR mutations are known in cancers (≥5% of colorectal cancer samples, in cutaneous melanoma, uterine, bladder, and stomach cancers, renal papillary cell carcinoma, glioblastoma multiforme), although none were reported as important for breast cancer development [26]. Here, NR3C2 is linked to breast carcinoma.